Project description
Psoriasis therapy using transdermal delivery
Psoriasis presents challenges in both treatment effectiveness and patient adherence. Supported by the Marie Skłodowska-Curie Actions programme, the SKINNOVATE project aims to develop an innovative dual-therapy concept combining a TNF-inhibitor and a small interfering RNA (siRNA) therapy, delivered through a novel transdermal method. This approach involves engineering hybrid lipid-polymer nanoparticles (LPNs) for the co-delivery of the two drugs, which will be incorporated into microneedle (MN) structures. The project will optimise the LPN formulation parameters, evaluate their physicochemical properties and biological performance in vitro, and assess the MN system’s skin penetration and therapeutic efficacy using ex vivo psoriasis models. By advancing this technology, SKINNOVATE aims to enhance treatment effectiveness, reduce side effects and improve patient adherence.
Objective
Psoriasis, affecting 2-3% of the global population and 20 million individuals in Europe, poses significant challenges in treatment efficacy and patient adherence to current therapies. Addressing these challenges, this project proposes an innovative therapeutic strategy by integrating Etanercept (ETR), a TNF- inhibitor, with small interfering RNA (siRNA) targeting IL-17A, facilitated through a novel transdermal delivery method. The project aims to develop and optimize hybrid lipid-polymer nanoparticles (LPNs) for co-delivering ETR and siRNA. These LPNs will be incorporated into microneedles (MNs) composed of biocompatible polymers, pectin, and polycaprolactone (PCL). This dual delivery approach leverages LPNs' controlled release properties and MNs' enhanced skin permeability to target multiple pathogenic pathways involved in psoriasis synergistically. Specific objectives include optimizing LPN formulation, evaluating efficacy in vitro, characterizing the MN system for skin penetration, and assessing performance in ex vivo psoriasis models, guided by ethical principles (3Rs: Replacement, Reduction, and Refinement). Expected outcomes encompass improved treatment efficacy, reduced adverse effects, and enhanced patient adherence, thereby advancing psoriasis management. Furthermore, this project seeks to catalyze interdisciplinary collaborations and propel the development of novel therapeutic strategies, contributing to scientific innovation and healthcare advancement.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences chemical sciences polymer sciences
- natural sciences biological sciences genetics RNA
- engineering and technology nanotechnology nano-materials
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-MSCA-2024-PF-01
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
9713 GZ Groningen
Netherlands
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.